{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.00","upperLimit":"8.00","value":"6.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.00","upperLimit":"24.00","value":"6.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The time to reach peak or maximum concentration (Tmax) was assessed. Actual recorded sampling times were considered for the calculations","dispersionType":"Full Range","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"}],"paramType":"MEDIAN","populationDescription":"The Pharmacokinetic Analysis Set (PAS) consisted of all patients who received at least one (full or partial) dose of LDK378 and provided at least one evaluable PK blood sample. Only the subset of participants with extensive PK collection were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1 at pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose. Cycle=21 days","title":"Tmax of LDK378","type":"SECONDARY","unitOfMeasure":"hours"}